Search PubMed⌕ Search

Biomedical subjects

R Clemens

Publications and source records attributed to R Clemens.

At least 73 records · Page 4Linked to original sources
PubMed1989

Antithrombin III substitution affects survival rate in a murine malaria model.

The effect of AT III substitution on survival time was studied in P. vinkei infected mice. One hundred mice were infected, randomly selected and allocated to two groups of 40 animals each on day 13 after infection. One group was placebo treated, the other group received 3 IU AT III daily on days 13 to 19. Comparison of the survival time in the log rank test showed a prolongation of the median survival time (5 versus 9 days, P less than 0.01). It is concluded that AT III might be beneficial in the treatment of severe malaria cases.

Animals↗
PubMed1989

[Substitution of F XIII concentrate in ulcerative colitis].

A 33 years old female with ulcerative colitis was admitted with an acute exacerbation of the disease characterised by haematochezia, diarrhoea (10 stools/die) and anaemia (haemoglobin 6.5 g/dl). Therapy with 5-ASA and corticosteroids for six weeks failed to decrease the activity of the disease. Since deficiency of coagulation factor XIII (activity 60%, subunit A 56%) was present, in addition, concentrates of factor XIII (Fibrogammin HS, Behring, F.R.G.) 1250 U/die were given for ten days. The substitution resulted in an immediate increase of reduced F XIII activity (164%) and F XIII subunit A (333%) as well as in a marked improvement of symptoms.

Adult↗
PubMed1988

Factor XIII: enzymatic and clinical aspects.

The present knowledge about clotting F XIII is roughly displayed. It is explained why F XIII is not a clotting factor in the strict sense of the word and that its biological function more general is the crosslinking of proteins via a transamidase reaction, the reduction of the permeability of the microvasculature, the stimulation of connective tissue cells, and finally the steering of connective tissue processes involved in wound healing. These effects are demonstrated as well in cell culture studies, animal experiments as by clinical results. Concerning the clinical results with F XIII, its effects on sclerodermia, subarachnoidal hemorrhage, inflammatory bowel diseases, Purpura Schönlein Henoch, and the wound healing are described in more detail.

Animals↗
PubMed1988

Applied kinesiology unreliable for assessing nutrient status.

Applied kinesiology is a technique used to assess nutritional status on the basis of the response of muscles to mechanical stress. In this study, 11 subjects were evaluated independently by three experienced applied kinesiologists for four nutrients (thiamin, zinc, vitamin A, and ascorbic acid). The results obtained by those applied kinesiologists were compared with (a) one another, (b) standard laboratory tests for nutrient status, and (c) computerized isometric muscle testing. Statistical analysis yielded no significant interjudge reliability, no significant correlation between the testers and standard biochemical tests for nutrient status, and no significant correlation between mechanical and manual determinations of relative muscle strength. In addition, the subjects were exposed in a double-blind fashion to supplements of thiamin, zinc, vitamin A, and ascorbic acid and two placebos (pectin and sucrose) and then re-tested. According to applied kinesiology theory, "weak" (indicating deficiency) muscles are strengthened when the subject is exposed to an appropriate nutritional supplement. Statistical analysis revealed no significant differences in the response to placebo, nutrients previously determined (by muscle testing) to be deficient, and nutrients previously determined (by muscle testing) to be adequate. Even though the number of subjects (11) and nutrients (4) tested was limited, the results of this study indicated that the use of applied kinesiology to evaluate nutrient status is no more useful than random guessing.

Adult↗
PubMed1987

Virus safety of a pasteurized antithrombin III concentrate. Preclinical and clinical data.

Blood derived products carry the risk of virus transmission, especially for the hepatitis B virus (HBV), non-A/non-B virus(es) (NANBV) and human immunodeficiency virus (HIV). The precautionary measures for guaranteeing the virus safety of the pasteurized antithrombin III concentrate Kybernin HS/P are described and the efficacy of these measures is demonstrated by in vitro studies and by chimpanzee trials. The inactivation rate is greater than or equal to 10(6.7) for HIV, greater than or equal to 10(6.7) for HBV, and greater than or equal to 10(5.3) for NANBV (Hutchinson Pool). Clinically, virus safety was demonstrated by long-term drug surveillance as well as by both a retrospective and prospective clinical trial. The 13 participants of the prospective study were checked clinically and biochemically according to the standards of the International Committee of Thrombosis and Hemostasis (ICTH). Within an observation period of 12 months, no seroconversion has been detected for HIV or HBV. Neither have any increases in the transaminases occurred which would indicate NANB hepatitis.

Alanine Transaminase↗
PubMed1984

[Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study].

The effectiveness of memantine on the symptoms of Parkinson's disease was investigated in 67 patients (39 males, 28 females) mostly between 55 and 75 years. The study was multi-center placebo-controlled with four treatment groups, i. e. patients with and without pre- and after-treatment with other anti-Parkinson medication receiving either placebo or memantine as sole or additional medication. The analysis of 61 evaluable cases showed a positive statistically significant influence on the single symptom tremor as well as on the neurological overall symptomatology (Webster-scale total score). Despite the inadequately ascertained mode of action memantine promises success particularly in milder and initial forms of the Parkinson syndrome either used as monotherapy or as an adjuvant.

Administration, Oral↗
PubMed1979

[Pain after nerve injuries (author's transl)].

After cut injuries to nerves, about 70% of the persons injured are stricken with painful hypersensitivity, and at least 50% with non-causalgic pain. Clinical reports on peace-time injuries have had scarce regard to both forms. In about 80% of the injured, the painful hypersensitivity sets in within 6 months of the surgical reconstruction and ceases in half of the the patients up to the end of the second year; in the other half the disturbances seem to persist much longer. Non-causalgic pain commence earlier than the painful hypersensitivity, often already shortly after the trauma. Complete remission of this pain is rare. In the event of greater intensity, both painful hypersensitivity and non-causalgic pain entail the risk of abuse of analgesics. As to differential diagnosis, non-causalgic pain must be discriminated from genuine causalgia in which continuous pain is superimposed by paroxysms of pain.

Analgesics↗
PubMed1979

[The monodigital recognition test (MRT)--a sensitivity-specific variant of Moberg's pick-up test].

The Test for Mono-digital Recognition (MRT) is a procedure specifically designed for the measurement of gnostic performance. The new test was derived from MOBERG's Pick-up Test with the aim of eliminating its shortcomings. Additional injuries do not restrict the applicability of the MRT and the test is not confined to the skin area supplied by the median nerve. The MRT expresses the degree of gnostic disturbances by means of a point system. For testing a patient only two to four minutes are needed.

Hand Injuries↗
PubMed1977

[Open study of befuraline (DIV 154) in 64 depressive patients (author's transl)].

The therapeutic efficacy of the new compound N-benzo[B]-furan-2-ylcarbonyl-N'-benzylpiperazine hydrochloride (befuraline) was evaluated in 64 patients presenting various depressive syndromes. Improvement was found in 33 cases (= 52%) under a daily dose of 150 mg befuraline; 31 of these patients improved within the first 8 days of treatment. Patients with endogenous depression responded favourably to the befuraline therapy, 23 (= 70%) of these (33) patients showing full recovery. Improvement was more frequently observed in patients with mild depression than in severe cases. It seems noteworthy that under befuraline treatment there was also a marked improvement in 21 cases in whom previous long-term therapy with other psychotropic drugs had remained ineffective. Side effects consisted mainly of reversible psycho-organic troubles; extrapyramidal disorders were not observed.

Adult↗
PubMed1976

Galactorrhea-amenorrhea syndromes: etiology and treatment.

Fifteen patients with galactorrhea-amenorrhea syndromes were studied before, during, and after treatment with bromergocryptine. Galactorrhea and amenorrhea were noted after pregnancy (6 patients), after oral contraceptive therapy (5 patients), and in association with pituitary adenoma (4 patients). Before treatment prolactin values were elevated ranging from 27 to 125 ng/ml, while luteinizing hormone and progesterone levels failed to show ovulatory peaks or luteal phase progression. Eleven patients had luteinizing hormone-releasing hormone tests before therapy. Response was normal in 8, subnormal in 2 pituitary adenoma, and supranormal in 1 patient with premature ovarian failure. Treatment with bromergocryptine was associated with a lowering of serum prolactin, cessation of lactation in all, and return of ovulatory menses in 14 of 15 patients. All relapsed when therapy was discontinued. Four patients became pregnant while on therapy. Long-term bromergocryptine therapy is effective for all forms of galactorrhea-amenorrhea syndromes studied.

Adenoma↗